Daily non-political popular news in brief.

Study shows liver an excellent target for cancer gene therapy using viral vectors

A featured paper in the Feb. 14 issue of Nature Cancer Gene Therapy demonstrates that cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.

Read more »

Keywords: study, shows, liver, excellent, target, cancer, gene, therapy, viral, vectors, show, vector

« Previous | Next »

Similar news on "Study shows liver an excellent target for cancer gene therapy using viral vectors":

1. Gene's activity points to more lethal subtype of AML
   07-09-2007 · EurekAlert!
   A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy. The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer.
   Similar news · Read more »
   
2. Targeted tumor therapy: When antagonists do the better job
   10-19-2006 · EurekAlert!
   Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed. These missiles, which should unerringly home in on the target and make it implode, consist of lethal payloads guided by small molecules -- known as agonists -- that recognize and then activate specific receptors over-expressed on the surface of tumor cells. A new study shows that it may be better to exploit small molecules that antagonize rather than activate receptors.
   Similar news · Read more »
   
3. Five-year study by OHSU Cancer Institute shows Gleevec's excellent survival rate
   12-06-2006 · EurekAlert!
   Today, after five years, the overall survival of 553 subjects randomized to receive Gleevec as their initial therapy is nearly 90 percent, 95 percent if only deaths related to CML are considered. Just 5 percent of subjects discontinued Gleevec because of side effects. The results are published in the Dec. 7 issue of the New England Journal of Medicine.
   Similar news · Read more »
   
4. Aggressive therapy best for certain AML patients
   08-01-2007 · EurekAlert!
   A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy. The findings apply to people with acute myeloid leukemia whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.
   Similar news · Read more »
   
5. Molecule blocks gene, sheds light on liver cancer
   08-01-2007 · EurekAlert!
   New research shows how a particular small molecule blocks the activity of a cancer-suppressing gene, allowing liver cancer cells to grow and spread. This molecule is a microRNA, a recently discovered class of tiny molecules used by cells to help control the kinds and amounts of proteins they make. More than 250 different microRNAs have been discovered, and several have been linked to cancer.
   Similar news · Read more »
   
6. Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
   10-24-2007 · EurekAlert!
   A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers presenting at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
   Similar news · Read more »
   
7. Gene therapy study shows safety and statistically significant improvement in Parkinson's disease
   06-21-2007 · EurekAlert!
   The first gene therapy trial for Parkinson's disease, an open label Phase 1 study in 12 patients with advanced disease, demonstrated both a lack of adverse events and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning).
   Similar news · Read more »
   
8. Huntington's disease study shows animal models on target
   07-31-2007 · EurekAlert!
   An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's disease closely resembles that of human HD patients.
   Similar news · Read more »
   
9. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
   09-23-2007 · EurekAlert!
   Italian scientists will announce on Monday (Sept. 24) that they have found a new and promising target for anti-tumor therapy in cancer. Professor Saverio Alberti, from the CESI, University of Chieti Foundation, Chieti, will tell the European Cancer Conference that he and his team have found a widespread mechanism for the stimulation of tumor growth in man, and that this is leading to the development of novel diagnostic and therapeutic procedures.
   Similar news · Read more »
   
10. New study reveals for first time how BRCA1 mutations cause breast cancer
    12-09-2007 · EurekAlert!
    An international team of researchers led by Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center and Sweden's Lund University has, for the first time, revealed how mutations in the BRCA1 gene lead to breast cancer. Findings show that one way BRCA1 mutations cause cancer is by knocking out a powerful tumor suppressor gene known as PTEN.
    Similar news · Read more »